Advertisement

Pharmaceutical Research

, 36:21 | Cite as

Spray Dried Smectite Clay Particles as a Novel Treatment against Obesity

  • Tahnee J. Dening
  • Paul Joyce
  • Miia Kovalainen
  • Hanna Gustafsson
  • Clive A. Prestidge
Research Paper
  • 32 Downloads

Abstract

Purpose

To explore the feasibility of spray dried smectite clay particles fabricated from montmorillonite or laponite materials for adsorbing dietary lipids and reducing rodent weight gain in vivo.

Methods

Spray dried montmorillonite (SD-MMT) and spray dried laponite (SD-LAP) particles were prepared via spray drying. Particle morphology, surface area and redispersion/aggregation properties in aqueous media were characterized. The ability of SD-MMT and SD-LAP particles to inhibit lipid digestion kinetics and adsorb lipid species from solution was assessed during in vitro lipolysis using proton nuclear magnetic resonance analysis. SD-MMT and SD-LAP particles were dosed to rodents fed a high-fat diet and their effect on body weight gain was evaluated.

Results

Both SD-MMT and SD-LAP particles adsorbed significant quantities of medium chain triglycerides and lipolytic products from solution during in vitro lipolysis. At a concentration of 50% w/w relative to lipid content, SD-MMT and SD-LAP particles adsorbed 42% and 94% of all lipid species, respectively. SD-MMT and SD-LAP particles also reduced the extent of rodent weight gain relative to the negative control treatment group and performed similarly to orlistat via an alternate mechanism of action.

Conclusions

Spray dried smectite clay particles (SD-MMT and SD-LAP) with significant adsorptive capacities for dietary lipids and digestion products were successfully fabricated. These particles may be developed as novel anti-obesity treatments with fewer adverse effects than currently marketed treatment options.

Key Words

digestion laponite lipid montmorillonite obesity 

Abbreviations

1H NMR

Proton nuclear magnetic resonance

AUC

Area under the curve

CEC

Cation exchange capacity

D(v,0.5)

Cumulative undersized volume fraction equal to 50%

DG

Diglyceride

FA

Fatty acid

Hmax

Maximum extent of lipid hydrolysis

MCT

Medium chain triglyceride

MG

Monoglyceride

PBS

Phosphate buffered saline

SD-LAP

Spray dried laponite

SD-MMT

Spray dried montmorillonite

SEM

Scanning electron microscopy

SSA

Specific surface area

TG

Triglyceride

Notes

Acknowledgments and Disclosures

The Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (ARC CE140100036) is gratefully acknowledged for research funding and support. The Australian Government Research Training Program is acknowledged for the PhD Scholarship of Tahnee J. Dening; the ÅForsk Foundation (16–463) and Wenner-Gren Foundation are acknowledged for the postdoctoral fellowship support and funding of Paul Joyce and Hanna Gustafsson; and, the Academy of Finland (#287625) is acknowledged for funding for the postdoctoral fellowship of Miia Kovalainen. This work was performed (in part) at the South Australian node of the Australian National Fabrication Facility under the National Collaborative Research Infrastructure Strategy.

References

  1. 1.
    Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2017;14:12–24.CrossRefGoogle Scholar
  2. 2.
    Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world — a growing challenge. N Engl J Med. 2007;356(3):213–5.CrossRefGoogle Scholar
  3. 3.
    Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev. 2011;12(2):131–41.CrossRefGoogle Scholar
  4. 4.
    Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the Management of Overweight and Obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. J Am Coll Cardiol. 2014;63(25, part B):2985-3023.Google Scholar
  5. 5.
    Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016;14(1):191.CrossRefGoogle Scholar
  6. 6.
    Drewnowski A, Specter SE. Poverty and obesity: the role of energy density and energy costs. Am J Clin Nutr. 2004;79(1):6–16.CrossRefGoogle Scholar
  7. 7.
    Bray GA, Popkin BM. Dietary fat intake does affect obesity! Am J Clin Nutr. 1998;68(6):1157–73.CrossRefGoogle Scholar
  8. 8.
    Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999;69(6):1108–16.CrossRefGoogle Scholar
  9. 9.
    Yamamoto H, Takemoto K, Tamura I, Shin-oka N, Nakano T, Nishida M, et al. Contribution of inorganic and organic components to sorption of neutral and ionizable pharmaceuticals by sediment/soil. Environ Sci Pollut Res. 2018;25(8):7250–61.CrossRefGoogle Scholar
  10. 10.
    Aguzzi C, Cerezo P, Viseras C, Caramella C. Use of clays as drug delivery systems: possibilities and limitations. Appl Clay Sci. 2007;36(1–3):22–36.CrossRefGoogle Scholar
  11. 11.
    Carmo AM, Hundal LS, Thompson ML. Sorption of hydrophobic organic compounds by soil materials: application of unit equivalent Freundlich coefficients. Environ Sci Technol. 2000;34(20):4363–9.CrossRefGoogle Scholar
  12. 12.
    Hundal LS, Thompson ML, Laird DA, Carmo AM. Sorption of Phenanthrene by reference Smectites. Environ Sci Technol. 2001;35(17):3456–61.CrossRefGoogle Scholar
  13. 13.
    Xu P, Dai S, Wang J, Zhang J, Liu J, Wang F, et al. Preventive obesity agent montmorillonite adsorbs dietary lipids and enhances lipid excretion from the digestive tract. Sci Rep. 2016;6:19659.CrossRefGoogle Scholar
  14. 14.
    Gershkovich P, Darlington J, Sivak O, Constantinides PP, Wasan KM. Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured Aluminosilicate compounds. J Pharm Sci. 2009;98(7):2390–400.CrossRefGoogle Scholar
  15. 15.
    Dening TJ, Joyce P, Rao S, Thomas N, Prestidge CA. Nanostructured montmorillonite clay for controlling the lipase-mediated digestion of medium chain triglycerides. ACS Appl Mater Interfaces. 2016;8(48):32732–42.CrossRefGoogle Scholar
  16. 16.
    Dening TJ, Rao S, Thomas N, Prestidge CA. Montmorillonite-lipid hybrid carriers for ionizable and neutral poorly water-soluble drugs: formulation, characterization and in vitro lipolysis studies. Int J Pharm. 2017;526(1–2):95–105.CrossRefGoogle Scholar
  17. 17.
    Dening TJ, Joyce P, Webber JL, Beattie DA, Prestidge CA. Inorganic surface chemistry and nanostructure controls lipolytic product speciation and partitioning during the digestion of inorganic-lipid hybrid particles. J Colloid Interface Sci. 2018;532:666–79.CrossRefGoogle Scholar
  18. 18.
    Sek L, Porter CJH, Kaukonen AM, Charman WN. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J Pharm Pharmacol. 2002;54(1):29–41.CrossRefGoogle Scholar
  19. 19.
    Joyce P, Barnes T, Boyd BJ, Prestidge CA. Porous nanostructure controls kinetics, disposition and self-assembly structure of lipid digestion products. RSC Adv. 2016;6:78385–95.CrossRefGoogle Scholar
  20. 20.
    Huang L, Chen J, Cao P, Pan H, Ding C, Xiao T, et al. Anti-obese effect of glucosamine and chitosan oligosaccharide in high-fat diet-induced obese rats. Marine Drugs. 2015;13(5):2732–56.CrossRefGoogle Scholar
  21. 21.
    Schoonheydt RA, Johnston CT. Chapter 5 - Surface and Interface Chemistry of Clay Minerals. In: Faïza B, Gerhard L, editors. Developments in Clay Science. Volume 5: Elsevier; 2013. p. 139–172.Google Scholar
  22. 22.
    Thompson DW, Butterworth JT. The nature of laponite and its aqueous dispersions. J Colloid Interface Sci. 1992;151(1):236–43.CrossRefGoogle Scholar
  23. 23.
    Pecini EM, Avena MJ. Measuring the isoelectric point of the edges of clay mineral particles: the case of montmorillonite. Langmuir. 2013;29(48):14926–34.CrossRefGoogle Scholar
  24. 24.
    Jatav S, Joshi YM. Chemical stability of Laponite in aqueous media. Appl Clay Sci. 2014;97–98:72–7.CrossRefGoogle Scholar
  25. 25.
    Ganley WJ, van Duijneveldt JS. Controlling clusters of colloidal platelets: effects of edge and face surface chemistries on the behavior of montmorillonite suspensions. Langmuir. 2015;31(15):4377–85.CrossRefGoogle Scholar
  26. 26.
    Tawari SL, Koch DL, Cohen C. Electrical double-layer effects on the Brownian diffusivity and aggregation rate of Laponite clay particles. J Colloid Interface Sci. 2001;240(1):54–66.CrossRefGoogle Scholar
  27. 27.
    Shahin A, Joshi YM. Irreversible aging dynamics and generic phase behavior of aqueous suspensions of Laponite. Langmuir. 2010;26(6):4219–25.CrossRefGoogle Scholar
  28. 28.
    Delgado A, González-Caballero F, Bruque JM. On the zeta potential and surface charge density of montmorillonite in aqueous electrolyte solutions. J Colloid Interface Sci. 1986;113(1):203–11.CrossRefGoogle Scholar
  29. 29.
    Tucci SA, Boyland EJ, Halford JCG. The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents. Diabetes Metab Syndr Obes. 2010;3:125–43.CrossRefGoogle Scholar
  30. 30.
    Whitby CP, Fornasiero D, Ralston J. Effect of oil soluble surfactant in emulsions stabilised by clay particles. J Colloid Interface Sci. 2008;323(2):410–9.CrossRefGoogle Scholar
  31. 31.
    Ganley WJ, van Duijneveldt JS. Controlling the rheology of montmorillonite stabilized oil-in-water emulsions. Langmuir. 2017;33(7):1679–86.CrossRefGoogle Scholar
  32. 32.
    Saunders JM, Goodwin JW, Richardson RM, Vincent B. A small-angle X-ray scattering study of the structure of aqueous Laponite dispersions. J Phys Chem B. 1999;103(43):9211–8.CrossRefGoogle Scholar
  33. 33.
    Abend S, Bonnke N, Gutschner U, Lagaly G. Stabilization of emulsions by Heterocoagulation of clay minerals and layered double hydroxides. Colloid Polym Sci. 1998;276(8):730–7.CrossRefGoogle Scholar
  34. 34.
    Ishiguro M, Koopal LK. Surfactant adsorption to soil components and soils. Adv Colloid Interf Sci. 2016;231:59–102.CrossRefGoogle Scholar
  35. 35.
    Jaynes W, Boyd S. Hydrophobicity of siloxane surfaces in smectites as revealed by aromatic hydrocarbon adsorption from water. Clay Clay Miner. 1991;39(4):428–36.CrossRefGoogle Scholar
  36. 36.
    van Olphen H. Internal mutual flocculation in clay suspensions. J Colloid Sci. 1964;19(4):313–22.CrossRefGoogle Scholar
  37. 37.
    Tan A, Martin A, Nguyen T-H, Boyd BJ, Prestidge CA. Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced Oral drug absorption. Angew Chem. 2012;124(22):5571–5.CrossRefGoogle Scholar
  38. 38.
    González R. Medina FSd, Martínez-Augustin O, Nieto a, Gálvez J, Risco S, et al. anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat. Br J Pharmacol. 2004;141(6):951–60.CrossRefGoogle Scholar
  39. 39.
    Khediri F, Mrad AI, Azzouz M, Doughi H, Najjar T, Mathiex-Fortunet H, et al. Efficacy of diosmectite (smecta) in the treatment of acute watery diarrhoea in adults: a multicentre, randomized, double-blind, placebo-controlled, parallel group study. Gastroenterol Research Pract. 2011;2011:783196.CrossRefGoogle Scholar
  40. 40.
    Roche. Xenical Product Information 2015 [Available from: http://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropxencp11214.
  41. 41.
    Castela-Papin N, Cai S, Vatier J, Keller F, Souleau CH, Farinotti R. Drug interactions with diosmectite: a study using the artificial stomach–duodenum model. Int J Pharm. 1999;182(1):111–9.CrossRefGoogle Scholar
  42. 42.
    Dening TJ, Thomas N, Rao S, van Looveren C, Cuyckens F, Holm R, et al. Montmorillonite and Laponite clay materials for the solidification of lipid-based formulations for the basic drug Blonanserin: in vitro and in vivo investigations. Mol Pharm. 2018;15:4148–60.CrossRefGoogle Scholar
  43. 43.
    McGinity JW, Lach JL. In vitro adsorption of various pharmaceuticals to montmorillonite. J Pharm Sci. 1976;65(6):896–902.CrossRefGoogle Scholar
  44. 44.
    Hunninghake DB, Hibbard DM. Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide. Clin Pharmacol Ther. 1986;39(3):329–34.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Tahnee J. Dening
    • 1
    • 2
  • Paul Joyce
    • 1
    • 3
  • Miia Kovalainen
    • 1
    • 4
  • Hanna Gustafsson
    • 1
    • 2
  • Clive A. Prestidge
    • 1
    • 2
  1. 1.School of Pharmacy and Medical SciencesUniversity of South AustraliaAdelaideAustralia
  2. 2.ARC Centre of Excellence in Convergent Bio-Nano Science and TechnologyUniversity of South AustraliaAdelaideAustralia
  3. 3.Department of PhysicsChalmers University of TechnologyGothenburgSweden
  4. 4.Research Unit of Biomedicine and Biocenter of Oulu, Faculty of MedicineUniversity of OuluOuloFinland

Personalised recommendations